JP2009511081A - 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 - Google Patents

条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 Download PDF

Info

Publication number
JP2009511081A
JP2009511081A JP2008536713A JP2008536713A JP2009511081A JP 2009511081 A JP2009511081 A JP 2009511081A JP 2008536713 A JP2008536713 A JP 2008536713A JP 2008536713 A JP2008536713 A JP 2008536713A JP 2009511081 A JP2009511081 A JP 2009511081A
Authority
JP
Japan
Prior art keywords
stem cells
cells
cell
stem
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008536713A
Other languages
English (en)
Japanese (ja)
Inventor
ジョン カムビアー，
ヨセフ リファエリ，
サラ ジョンソン，
ブライアン カーティス ターナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
National Jewish Health
Original Assignee
University of Colorado Boulder
National Jewish Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder, National Jewish Health filed Critical University of Colorado Boulder
Publication of JP2009511081A publication Critical patent/JP2009511081A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
JP2008536713A 2005-10-18 2006-10-18 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 Pending JP2009511081A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72813105P 2005-10-18 2005-10-18
US76599306P 2006-02-06 2006-02-06
PCT/US2006/040379 WO2007047583A2 (en) 2005-10-18 2006-10-18 Conditionally immortalized long-term stem cells and methods of making and using such cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012221023A Division JP5726148B2 (ja) 2005-10-18 2012-10-03 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。

Publications (1)

Publication Number Publication Date
JP2009511081A true JP2009511081A (ja) 2009-03-19

Family

ID=37963171

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2008536713A Pending JP2009511081A (ja) 2005-10-18 2006-10-18 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法
JP2012221023A Expired - Fee Related JP5726148B2 (ja) 2005-10-18 2012-10-03 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2014108137A Expired - Fee Related JP6302356B2 (ja) 2005-10-18 2014-05-26 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2016027812A Pending JP2016129515A (ja) 2005-10-18 2016-02-17 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2017166334A Expired - Fee Related JP6655050B2 (ja) 2005-10-18 2017-08-31 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2019006759A Expired - Fee Related JP6797221B2 (ja) 2005-10-18 2019-01-18 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2020119082A Expired - Fee Related JP7078673B2 (ja) 2005-10-18 2020-07-10 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2022025236A Pending JP2022065146A (ja) 2005-10-18 2022-02-22 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2012221023A Expired - Fee Related JP5726148B2 (ja) 2005-10-18 2012-10-03 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2014108137A Expired - Fee Related JP6302356B2 (ja) 2005-10-18 2014-05-26 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2016027812A Pending JP2016129515A (ja) 2005-10-18 2016-02-17 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2017166334A Expired - Fee Related JP6655050B2 (ja) 2005-10-18 2017-08-31 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2019006759A Expired - Fee Related JP6797221B2 (ja) 2005-10-18 2019-01-18 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2020119082A Expired - Fee Related JP7078673B2 (ja) 2005-10-18 2020-07-10 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
JP2022025236A Pending JP2022065146A (ja) 2005-10-18 2022-02-22 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。

Country Status (12)

Country Link
US (7) US8883507B2 (enExample)
EP (1) EP1942739B1 (enExample)
JP (8) JP2009511081A (enExample)
KR (2) KR101441693B1 (enExample)
CN (2) CN105483088B (enExample)
AT (1) ATE491022T1 (enExample)
AU (1) AU2006304392B2 (enExample)
CA (2) CA3065947C (enExample)
DE (1) DE602006018768D1 (enExample)
IL (7) IL286053B2 (enExample)
IN (1) IN2014DN06624A (enExample)
WO (1) WO2007047583A2 (enExample)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011034073A1 (ja) * 2009-09-15 2011-03-24 国立大学法人東京大学 分化細胞の新規製造法
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
JP2014158503A (ja) * 2005-10-18 2014-09-04 National Jewish Health 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
JP2015524415A (ja) * 2012-07-20 2015-08-24 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
US9169462B2 (en) 2008-07-21 2015-10-27 Taiga Biotechnologies, Inc. Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
JP2016510996A (ja) * 2013-03-11 2016-04-14 タイガ バイオテクノロジーズ，インク． 成体幹細胞のインビトロでの増殖
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
JP2020525031A (ja) * 2017-06-30 2020-08-27 エタブリスモン フランセ ドュ サンＥｔａｂｌｉｓｓｅｍｅｎｔ Ｆｒａｎｃａｉｓ Ｄｕ Ｓａｎｇ 赤血球系前駆細胞を作製する方法
US10864259B2 (en) 2017-08-03 2020-12-15 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US11116796B2 (en) 2016-12-02 2021-09-14 Taiga Biotechnologies, Inc. Nanoparticle formulations
JP2022513355A (ja) * 2018-10-12 2022-02-07 リニューロン リミテッド 条件付き不死化に関する制御可能な導入遺伝子を含む人工多能性細胞
WO2023277153A1 (ja) * 2021-06-30 2023-01-05 国立大学法人千葉大学 骨髄系共通前駆細胞（ｃｍｐ）又は骨髄球系前駆細胞の増殖性を向上させる方法
US12250943B2 (en) 2019-04-08 2025-03-18 Htyr Acquisition Llc Compositions and methods for the cryopreservation of immune cells
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2772535T (pt) 2006-05-31 2022-07-04 Childrens Medical Center Células estaminais mesenquimais abcb5 positivas como imunomoduladores
GB0619500D0 (en) * 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
US8551968B2 (en) 2007-03-13 2013-10-08 National Jewish Health Methods for generation of antibodies
ES2796111T3 (es) 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2011002721A1 (en) * 2009-06-29 2011-01-06 Leskov Ilya B Non-human mammal model of human hematopoietic cancer
AU2014240253B2 (en) * 2009-09-15 2017-08-03 The University Of Tokyo Novel Method for Producing Differentiated Cells
DK2498796T3 (en) * 2009-11-09 2018-03-05 Aal Scient Inc HEART DISEASE TREATMENT
WO2011138786A2 (en) * 2010-05-06 2011-11-10 Stem Cell Medicine Ltd. Stem cell bank for personalized medicine
JP5861191B2 (ja) * 2010-09-30 2016-02-16 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
US20130171115A1 (en) * 2011-12-30 2013-07-04 Gang Li Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene
KR102385934B1 (ko) 2013-02-19 2022-04-13 칠드런'즈 메디컬 센터 코포레이션 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포
WO2014182994A1 (en) 2013-05-10 2014-11-13 Children's Medical Center Corporation Wound healing and tissue engineering
KR101638403B1 (ko) * 2013-07-17 2016-07-11 아주대학교산학협력단 RGMc를 유효성분으로 포함하는 줄기세포 유도용 배지 조성물 및 이를 이용한 줄기세포의 유도방법
WO2015020993A2 (en) * 2013-08-05 2015-02-12 The Trustees Of The University Of Pennsylvania RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA
CN103509101B (zh) * 2013-08-12 2016-11-02 中国科学院广州生物医药与健康研究院 一种扩增脐带血造血干细胞的细胞因子及其培养基
US20180051253A1 (en) 2015-03-18 2018-02-22 The Regents Of The University Of California Methods of preventing and reversing stem cell aging
CN106148266A (zh) * 2015-04-20 2016-11-23 烟台赛泽生物技术有限公司 一种免疫细胞用培养基及该培养基的添加剂
CN104928247B (zh) * 2015-07-02 2018-03-23 广州赛莱拉干细胞科技股份有限公司 一种神经干细胞培养基及神经干细胞贴壁培养方法
JP2018520688A (ja) 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
US10525082B2 (en) * 2015-09-09 2020-01-07 Seattle Children's Hospital Genetic engineering of macrophages for immunotherapy
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
CN105695511B (zh) * 2016-04-13 2025-01-21 中国人民解放军第三军医大学 一种永生化毛囊干细胞系及其制备方法
CN105713880A (zh) * 2016-04-20 2016-06-29 广东艾时代生物科技有限责任公司 一种造血干细胞体外扩增培养的无血清培养基及其应用
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106754728B (zh) * 2016-12-30 2020-05-15 中国人民解放军总医院 后肾间充质细胞系及其制备方法与应用
EP3661953A4 (en) * 2017-08-03 2021-04-14 Taiga Biotechnologies, Inc. CANCER TREATMENT METHODS AND COMPOSITIONS
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
US12023357B2 (en) 2017-10-13 2024-07-02 Hackensack University Medical Center Rejuvenated aged hematopoietic stem cells and methods of use
CN107937342B (zh) * 2017-11-06 2021-07-06 中国人民解放军第四军医大学 一种通过内皮细胞来源的外泌体扩增神经干细胞的方法
CN108070567A (zh) * 2018-01-19 2018-05-25 皓昇莱生物制药有限公司 一种永生化的尿液来源细胞株及其构建方法
JP7611701B2 (ja) 2018-04-25 2025-01-10 ザ チルドレンズ メディカル センター コーポレーション Ａｂｃｂ５のリガンドおよび基質
GB201902068D0 (en) * 2019-02-14 2019-04-03 Cambridge Entpr Ltd Methods of reactivating proliferative capacity non-proliferative tissues
CN114729324A (zh) * 2019-07-24 2022-07-08 斯比根公司 永生化干细胞株的制备方法及其用途
CN110622921B (zh) * 2019-09-29 2021-06-15 江苏大学 阿尔茨海默病病变区FoxG1过表达小鼠模型的构建方法及应用
GB202005494D0 (en) * 2020-04-15 2020-05-27 Reneuron Ltd Induced pluripotent cell comprising a contollable transgene for conditional immortalisation
KR20220057859A (ko) 2020-10-30 2022-05-09 전상수 펜터리
US20230407268A1 (en) 2020-11-06 2023-12-21 Trans Chromosomics, Inc. Method for producing reversibly immortalized cell
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113583965A (zh) * 2021-08-05 2021-11-02 大连干细胞与精准医学创新研究院 一种条件永生化人神经干细胞来源细胞膜纳米囊泡制剂及其制备方法和应用
WO2023069881A1 (en) * 2021-10-20 2023-04-27 University Of Rochester Treatment with genetically modified cells, and genetically modified cells per se, with increased competitive advantage and/or decreased competitive disadvantage
JP7773257B2 (ja) 2022-03-28 2025-11-19 合同会社HiRoko Science ｍｉＲ－１４０を含む医薬組成物及びその製造方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518300A (ja) * 1997-09-26 2001-10-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム Ｈｉｖ−１ｔａｔ及び／又はｎｅｆタンパク質を含んで成る融合タンパク質
WO2003097675A1 (en) * 2002-05-16 2003-11-27 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
JP2004537293A (ja) * 2001-05-31 2004-12-16 ノバルティス アクチエンゲゼルシャフト 新規なエストロゲン受容体リガンド結合ドメイン変異体及び新規なリガンド及び医薬組成物
JP2005523012A (ja) * 2002-04-16 2005-08-04 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌モデル
JP2005525085A (ja) * 2001-11-01 2005-08-25 ジェンファー インコーポレイテッド ヒト免疫不全ウイルスに対する遺伝子ワクチン
JP2005527227A (ja) * 2002-05-29 2005-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 誘導性の真核生物発現システム

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
EP0207147A4 (en) * 1984-12-21 1988-07-14 Techniclone Res Partners METHOD OF ELECTRICAL IMMORTALIZATION OF LYMPHOID CELLS.
DE3531430A1 (de) 1985-09-03 1987-03-05 Biotest Pharma Gmbh Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten
US4963489A (en) * 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US4900322A (en) 1986-09-22 1990-02-13 Adams James D Blood component pooling valve and kit
US5476996A (en) * 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5849288A (en) * 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5843728A (en) 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
AU781922B2 (en) 1991-12-17 2005-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5289858A (en) 1991-12-18 1994-03-01 Abbott Laboratories System for accommodating withdrawal of liquid from a bulk supply
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
DE69321962T2 (de) 1992-08-21 1999-07-01 Biogen Inc Von tat abgeleitete transportpolypeptide
US5580760A (en) 1993-02-22 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services FUSE binding protein and cDNA therefor
EP0710283A4 (en) * 1993-07-22 1997-07-02 Merck & Co Inc THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL
US5599705A (en) 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
ES2204944T3 (es) 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6713247B1 (en) * 1996-09-03 2004-03-30 Signal Pharmaceuticials, Inc. Human CNS cell lines and methods of use therefor
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
EP0893493A3 (de) * 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen
CA2314267A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
DE69923550T2 (de) 1998-04-08 2006-02-16 Shionogi & Co., Ltd. Verfahren um Vorläuferzellen von Osteoklasten zu isolieren und ihre Differenzierung in Osteoklasten zu induzieren.
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
US6451558B1 (en) * 1998-08-03 2002-09-17 Novartis Ag Genes in the control of hematopoiesis
US6913925B1 (en) * 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
EP1157275A4 (en) 1999-02-28 2003-01-15 Univ Washington NOVEL TRANSDUCTION MOLECULES AND METHODS OF USING THE SAME
WO2000059540A1 (en) 1999-04-05 2000-10-12 Biocrystal Ltd. Assay kits and methods for immune complex-mediated activation involving shed antigens
DE60031260T2 (de) 1999-04-12 2007-05-03 Heart Biosystems Gmbh Vorübergehend-immortalisierte zellen zur verwendung in gentherapie
US6451601B1 (en) * 1999-04-12 2002-09-17 Modex Therapeutiques, S.A. Transiently immortalized cells for use in gene therapy
US6358739B1 (en) 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US7135287B1 (en) * 1999-10-02 2006-11-14 Biosite, Inc. Human antibodies
US7311920B1 (en) * 1999-10-08 2007-12-25 University Of Maryland Biotechnology Institute Virus coat protein/receptor chimeras and methods of use
AU1482101A (en) * 1999-11-10 2001-06-06 Rigel Pharmaceuticals, Inc. Methods and compositions comprising renilla gfp
EP1103615A1 (en) 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
US20010049393A1 (en) * 1999-12-07 2001-12-06 Whitehead Institute For Biomedical Research Methods for defining MYC target genes and uses thereof
WO2001087058A1 (en) * 2000-05-15 2001-11-22 Sonoko Habu Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US20070248618A1 (en) * 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
ATE428790T1 (de) 2000-09-25 2009-05-15 Genetronics Inc Verbessertes system zur regulation der transgenexpression
WO2002036738A2 (en) 2000-10-30 2002-05-10 Kalobios, Inc. Affinity maturation by competitive selection
AU2002228722B2 (en) 2000-11-01 2007-01-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Expression vectors able to elicit improved immune response and methods of using same
EP1338198B1 (en) * 2000-12-01 2007-11-28 Central Institute For Experimental Animals Method of constructing mouse suitable for the take, differentiation and proliferation of heterogenous cells, mouse constructed by this method and use of the mouse
WO2002057436A2 (en) 2001-01-19 2002-07-25 Gendel Limited Red blood cell from a transgenic animal as vehicle for polypeptide delivery
US7033744B2 (en) * 2001-03-16 2006-04-25 Naoya Kobayashi Method for proliferating a liver cell, a liver cell obtained thereby, and use thereof
EP1421115B1 (en) 2001-08-31 2005-03-02 Avidex Limited Soluble t cell receptor
CN1408850A (zh) * 2001-09-18 2003-04-09 王虹 人血树突状细胞永生化技术
CN100506978C (zh) 2001-09-21 2009-07-01 中国人民解放军军事医学科学院野战输血研究所 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
CA2466138A1 (en) 2001-11-02 2003-05-15 Shen Wu Wang B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
EP1321034A1 (en) * 2001-12-21 2003-06-25 Pfizer Products Inc. Disruption of the phosphodieterase 10 gene
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20030216315A1 (en) 2002-02-13 2003-11-20 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
US7211191B2 (en) 2004-09-30 2007-05-01 Thermogenesis Corp. Blood component separation method and apparatus
GB2387599B (en) 2002-04-17 2005-08-10 Jason Peter Brown Methods for producing antibodies
CA2485363C (en) * 2002-05-10 2014-10-28 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
EP1545204B1 (en) 2002-09-06 2016-08-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
DE50209178D1 (de) * 2002-10-11 2007-02-15 Imvision Gmbh Moduläre Antigen-Transporter Moleküle (MAT-Moleküle) zur Modulierung von Immunreaktionen, zugehörige Konstrukte, Verfahren und Verwendungen
AU2003274633A1 (en) 2002-10-15 2004-05-04 Ramot At Tel-Aviv University Ltd. Erythrocyte differentiation factor, gene encoding same, and methods of use thereof
ES2327229T3 (es) 2002-11-09 2009-10-27 Immunocore Ltd. Presentacion del receptor de linfocitos t.
JP2006509010A (ja) 2002-12-05 2006-03-16 インペリアル・カレッジ・イノベイションズ・リミテッド アポトーシスの制御
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US7482016B2 (en) 2003-03-19 2009-01-27 The J. David Gladstone Institutes Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
DK1623017T3 (da) 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
WO2005014785A2 (en) 2003-06-18 2005-02-17 The George Washington University Conditionally-immortalized hematopoietic progenitor cell lines
WO2005084158A2 (en) * 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
IL161903A0 (en) 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
US7705049B2 (en) * 2004-01-21 2010-04-27 New York University Methods for treating non-melanoma cancers with PABA
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
JP4773434B2 (ja) 2004-05-19 2011-09-14 イムノコア リミテッド 高親和性ｎｙ−ｅｓｏｔ細胞受容体
EP1756278B1 (en) 2004-05-19 2008-09-17 MediGene Ltd. Method of improving t cell receptors
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US20060068469A1 (en) 2004-08-17 2006-03-30 Research Development Foundation Bacterial vector systems
GB0420963D0 (en) * 2004-09-21 2004-10-20 Reneuron Ltd Hepatocyte
WO2006045064A2 (en) * 2004-10-20 2006-04-27 Whitehead Institute For Biomedical Research Cultured hematopoietic stem cells and method for expansion and analysis thereof
WO2007067183A1 (en) 2005-12-09 2007-06-14 The Regents Of The University Of California Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells
US20060156422A1 (en) * 2005-01-10 2006-07-13 Medical Research Council Methods and compositions for the generation of antibodies
JP2008535823A (ja) 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
CA2609342A1 (en) 2005-04-26 2006-11-02 Andrei L. Gartel Nucleoside compounds and methods of use thereof
EP1885754B1 (en) 2005-05-25 2011-02-09 Immunocore Ltd. T cell receptors which specifically bind to vygfvracl-hla-a24
CA2620364A1 (en) * 2005-08-26 2007-03-01 David C. Yeomans Methods for treatment of headaches by administration of oxytocin
US20070047583A1 (en) 2005-08-29 2007-03-01 Siemens Aktiengesellschaft Method for using a short address in a packet header
KR101441693B1 (ko) 2005-10-18 2014-09-25 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및사용 방법
JP4929288B2 (ja) * 2005-11-04 2012-05-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｎａｖ１．８遺伝子の発現を抑制するための組成物および方法
EP1792627A1 (en) 2005-12-05 2007-06-06 ImVisioN AG Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
WO2008038002A2 (en) 2006-09-29 2008-04-03 Medigene Limited T cell therapies
US8551968B2 (en) 2007-03-13 2013-10-08 National Jewish Health Methods for generation of antibodies
US20110218210A1 (en) 2007-11-02 2011-09-08 Taiga Biotechnologies Compounds for treating abnormal cellular proliferation
WO2009117439A2 (en) 2008-03-17 2009-09-24 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
SG190661A1 (en) * 2008-05-16 2013-06-28 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
US8481492B2 (en) 2008-06-13 2013-07-09 Life & Brain Gmbh Fusion protein and use thereof
ES2525411T3 (es) * 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
JP5812861B2 (ja) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
CA3012803C (en) 2008-11-06 2023-08-08 Indiana University Research & Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
CA2743669C (en) 2008-11-24 2018-10-16 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) High affinity t cell receptor and use thereof
WO2011100477A2 (en) 2010-02-10 2011-08-18 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US20120107317A1 (en) 2010-10-27 2012-05-03 The University Of Hong Kong Use of cytoplasmic c-myc for regulating immune responses
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP3392270B1 (en) 2011-09-15 2020-08-26 The United States of America, as Represented by the Secretary Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
US9751928B2 (en) 2012-05-03 2017-09-05 Fred Hutchinson Cancer Research Center Enhanced affinity T cell receptors and methods for making the same
DE102012209673A1 (de) 2012-06-08 2013-12-24 Artcline Gmbh Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
CN104684926B (zh) 2012-07-27 2022-04-08 伊利诺伊州大学理事会 工程化t细胞受体
US20140109246A1 (en) 2012-09-24 2014-04-17 The Regents Of The University Of Colorado, A Body Corporate Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species
GB2508414A (en) 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
WO2014133568A1 (en) 2013-03-01 2014-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood
AU2013379772B2 (en) 2013-03-01 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive T cells from tumor
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
CA2945393C (en) 2014-04-24 2021-03-23 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
CN107427573B (zh) 2014-12-24 2022-12-27 耐克西缪恩有限公司 用于免疫疗法的纳米颗粒组合物和方法
WO2017123978A1 (en) 2016-01-15 2017-07-20 Berkeley Lights, Inc. Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518300A (ja) * 1997-09-26 2001-10-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム Ｈｉｖ−１ｔａｔ及び／又はｎｅｆタンパク質を含んで成る融合タンパク質
JP2004537293A (ja) * 2001-05-31 2004-12-16 ノバルティス アクチエンゲゼルシャフト 新規なエストロゲン受容体リガンド結合ドメイン変異体及び新規なリガンド及び医薬組成物
JP2005525085A (ja) * 2001-11-01 2005-08-25 ジェンファー インコーポレイテッド ヒト免疫不全ウイルスに対する遺伝子ワクチン
JP2005523012A (ja) * 2002-04-16 2005-08-04 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌モデル
WO2003097675A1 (en) * 2002-05-16 2003-11-27 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
JP2005527227A (ja) * 2002-05-29 2005-09-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 誘導性の真核生物発現システム

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150831B2 (en) 2005-10-18 2015-10-06 The Regents Of The University Of Colorado Conditionally immortalized long-term stem cells and methods of making and using such cells
US10760055B2 (en) 2005-10-18 2020-09-01 National Jewish Health Conditionally immortalized long-term stem cells and methods of making and using such cells
JP2014158503A (ja) * 2005-10-18 2014-09-04 National Jewish Health 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
US8883507B2 (en) 2005-10-18 2014-11-11 The Regents Of The University Of Colorado Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells
US10442853B2 (en) 2008-05-16 2019-10-15 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US9428571B2 (en) 2008-05-16 2016-08-30 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US11667695B2 (en) 2008-05-16 2023-06-06 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US9169462B2 (en) 2008-07-21 2015-10-27 Taiga Biotechnologies, Inc. Methods for preparing mature erythrocytes from conditionally immortalized hematopoietic stem cells
US11369678B2 (en) 2008-08-28 2022-06-28 Taiga Biotechnologies, Inc. Compositions and methods for modulating immune cells
US12496341B2 (en) 2008-08-28 2025-12-16 Htyr Acquisition Llc Methods for reducing anergy in lymphocytes using modulators of MYC
US10556006B2 (en) 2008-08-28 2020-02-11 Taiga Biotechnologies, Inc. Compositions and methods for modulating an immune response
US8784825B2 (en) 2008-08-28 2014-07-22 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
US9775897B2 (en) 2008-08-28 2017-10-03 Taiga Biotechnologies, Inc. Modulators of MYC and methods of using the same
US8828723B2 (en) 2008-08-28 2014-09-09 Taiga Biotechnologies, Inc. Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC
US9200254B2 (en) 2009-09-15 2015-12-01 The University Of Tokyo Method for producing differentiated cells
JP2015130866A (ja) * 2009-09-15 2015-07-23 国立大学法人 東京大学 分化細胞の新規製造法
JP2015213520A (ja) * 2009-09-15 2015-12-03 国立大学法人 東京大学 分化細胞の新規製造法
JP2017046719A (ja) * 2009-09-15 2017-03-09 国立大学法人 東京大学 分化細胞の新規製造法
CN102712906B (zh) * 2009-09-15 2015-09-30 国立大学法人东京大学 分化细胞的新型制备方法
WO2011034073A1 (ja) * 2009-09-15 2011-03-24 国立大学法人東京大学 分化細胞の新規製造法
KR101834687B1 (ko) * 2009-09-15 2018-03-05 고쿠리츠다이가쿠호우진 도쿄다이가쿠 분화 세포의 신규 제조법
US10087419B2 (en) 2009-09-15 2018-10-02 The University Of Tokyo Method for producing differentiated cells
JP5791191B2 (ja) * 2009-09-15 2015-10-07 国立大学法人 東京大学 分化細胞の新規製造法
CN102712906A (zh) * 2009-09-15 2012-10-03 国立大学法人东京大学 分化细胞的新型制备方法
JP2021088608A (ja) * 2012-07-20 2021-06-10 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
JP2022145801A (ja) * 2012-07-20 2022-10-04 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
JP2015524415A (ja) * 2012-07-20 2015-08-24 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
US10206952B2 (en) 2012-07-20 2019-02-19 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
JP2019178180A (ja) * 2012-07-20 2019-10-17 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
JP2018095654A (ja) * 2012-07-20 2018-06-21 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
JP7122424B2 (ja) 2012-07-20 2022-08-19 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
US9789135B2 (en) 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10953048B2 (en) 2012-07-20 2021-03-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
JP2016510996A (ja) * 2013-03-11 2016-04-14 タイガ バイオテクノロジーズ，インク． 成体幹細胞のインビトロでの増殖
US10786534B2 (en) 2013-03-11 2020-09-29 Taiga Biotechnologies, Inc. Production and use of red blood cells
JP2018088936A (ja) * 2013-03-11 2018-06-14 タイガ バイオテクノロジーズ，インク． 成体幹細胞のインビトロでの増殖
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10087420B2 (en) 2013-03-11 2018-10-02 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US11116796B2 (en) 2016-12-02 2021-09-14 Taiga Biotechnologies, Inc. Nanoparticle formulations
US12344658B2 (en) 2016-12-02 2025-07-01 HTYR Acquistion LLC Nanoparticle formulations
JP2020525031A (ja) * 2017-06-30 2020-08-27 エタブリスモン フランセ ドュ サンＥｔａｂｌｉｓｓｅｍｅｎｔ Ｆｒａｎｃａｉｓ Ｄｕ Ｓａｎｇ 赤血球系前駆細胞を作製する方法
JP7162625B2 (ja) 2017-06-30 2022-10-28 エタブリスモン フランセ ドュ サン 赤血球系前駆細胞を作製する方法
US10864259B2 (en) 2017-08-03 2020-12-15 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
JP2022513355A (ja) * 2018-10-12 2022-02-07 リニューロン リミテッド 条件付き不死化に関する制御可能な導入遺伝子を含む人工多能性細胞
US12250943B2 (en) 2019-04-08 2025-03-18 Htyr Acquisition Llc Compositions and methods for the cryopreservation of immune cells
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion
WO2023277153A1 (ja) * 2021-06-30 2023-01-05 国立大学法人千葉大学 骨髄系共通前駆細胞（ｃｍｐ）又は骨髄球系前駆細胞の増殖性を向上させる方法

Also Published As

Publication number Publication date
JP6797221B2 (ja) 2020-12-09
ATE491022T1 (de) 2010-12-15
CA3065947C (en) 2023-03-07
EP1942739A2 (en) 2008-07-16
WO2007047583A2 (en) 2007-04-26
HK1222890A1 (zh) 2017-07-14
JP5726148B2 (ja) 2015-05-27
JP6302356B2 (ja) 2018-03-28
WO2007047583A3 (en) 2007-11-22
IL266009B (en) 2021-06-30
HK1126623A1 (zh) 2009-09-11
CN105483088B (zh) 2021-05-28
CA3065947A1 (en) 2007-04-26
KR20080070005A (ko) 2008-07-29
CN105483088A (zh) 2016-04-13
US20100297763A1 (en) 2010-11-25
AU2006304392A1 (en) 2007-04-26
JP2017221219A (ja) 2017-12-21
US8883507B2 (en) 2014-11-11
IL286053A (en) 2021-10-31
IL224494B (en) 2018-01-31
IL190946A (en) 2016-09-29
EP1942739A4 (en) 2009-09-16
IL286053B2 (en) 2023-03-01
JP2016129515A (ja) 2016-07-21
JP2022065146A (ja) 2022-04-26
EP1942739B1 (en) 2010-12-08
IL256512B (en) 2019-05-30
AU2006304392B2 (en) 2014-05-01
US9150831B2 (en) 2015-10-06
CA2626525C (en) 2020-03-10
IL190946A0 (en) 2008-12-29
IL256512A (en) 2018-02-28
IN2014DN06624A (enExample) 2015-07-10
CN101330830A (zh) 2008-12-24
AU2006304392A8 (en) 2008-05-29
KR101441843B1 (ko) 2014-09-17
JP2019062916A (ja) 2019-04-25
US20200308545A1 (en) 2020-10-01
IL296832A (en) 2022-11-01
JP2013017486A (ja) 2013-01-31
JP7078673B2 (ja) 2022-05-31
JP6655050B2 (ja) 2020-02-26
US20190024051A1 (en) 2019-01-24
US20160040129A1 (en) 2016-02-11
IL278426B (en) 2021-09-30
US20070116691A1 (en) 2007-05-24
US10760055B2 (en) 2020-09-01
CN101330830B (zh) 2016-01-20
CA2626525A1 (en) 2007-04-26
JP2014158503A (ja) 2014-09-04
US9796961B2 (en) 2017-10-24
DE602006018768D1 (de) 2011-01-20
IL286053B (en) 2022-11-01
JP2020174675A (ja) 2020-10-29
US20220145253A1 (en) 2022-05-12
KR20130131488A (ko) 2013-12-03
KR101441693B1 (ko) 2014-09-25
IL266009A (en) 2019-05-30
US20150240205A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
JP7078673B2 (ja) 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。
CN112063586A (zh) 用于人造血干/祖细胞的离体扩增的组合物和方法
Pritchard et al. Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms
AU2014202016B2 (en) Conditionally immortalized long-term stem cells and methods of making and using such cells
ES2357627T3 (es) Células madre adultas inmortalizadas en forma condicional a largo plazo y métodos para hacer y utilizar tales células.
HK1126623B (en) Conditionally immortalized long-term stem cells and methods of making and using such cells
HK1222890B (zh) 条件无限增殖化长期干细胞和制备和使用所述细胞的方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091016

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20091028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20091028

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131205